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Acute lung injury (ALI) is a heterogeneous inﬂammatory condition associated
with high morbidity and mortality. Neutrophils play a key role in the
development of different forms of ALI, and the release of neutrophil
extracellular traps (NETs) is emerging as a common pathogenic mechanism.
NETs are essential in controlling pathogens, and their defective release or
increased degradation leads to a higher risk of infection. However, NETs also
contain several pro-inﬂammatory and cytotoxic molecules than can
exacerbate thromboinﬂammation and lung tissue injury. To reduce NETmediated lung damage and inﬂammation, DNase is frequently used in
preclinical models of ALI due to its capability of digesting NET DNA scaffold.
Moreover, recent advances in neutrophil biology led to the development of
selective NET inhibitors, which also appear to reduce ALI in experimental
models. Here we provide an overview of the role of NETs in different forms
of ALI discussing existing gaps in our knowledge and novel therapeutic
approaches to modulate their impact on lung injury.
KEYWORDS

NETs (neutrophil extracellular traps), ALI (acute lung injury), ARDS (acute respiratory distress
syndrome), sterile inﬂammatory response, infections and sepsis, COVID-19, DAMPs (damageassociated molecular patterns), Thromboinﬂammation

Introduction
ALI is an inﬂammatory condition characterized by the acute onset of lung tissue
damage and pulmonary dysfunction originating from infectious or sterile insults (1).
Typical features of ALI are the alveolar accumulation of protein-rich ﬂuid and activated
immune cells due to pulmonary endothelial barrier disruption and increased vascular
permeability (2). The pathological alterations of ALI are responsible for a clinical
syndrome characterized by extensive non-cardiogenic pulmonary edema and
decreasing oxygenation, also known as acute respiratory distress syndrome (ARDS)
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19). Finally, a third type of fast, vital and ROS-dependent
NETosis was recently described in response to granulocytemacrophage colony-stimulating factor or lipopolysaccharide
(LPS) leading to the release of mitochondrial DNA (mtDNA)
mixed with granule proteins (7).
Almost two decades after the ﬁrst observations, it is now
commonly accepted that NET release can occur in response to
multiple stimuli via several and frequently interconnected
activation pathways (17, 20–22) that are not necessarily
associated with neutrophil death (7, 18, 19). Regardless of the
stimuli and the activation mechanisms, NET composition has
intrinsic pro-inﬂammatory characteristics due to the presence of
granule-derived proteases, histones and cell-free DNA (23).

(3). ARDS is associated with high morbidity and mortality
(~40%), and its increasing incidence, particularly related to the
recent COVID-19 pandemic, represents a signiﬁcant global
burden (4).
Airway neutrophilia has been historically considered a
hallmark of ARDS (5). However, the underlying mechanisms
that control neutrophil contribution to ALI are not fully
understood. Although neutrophils play well-established
functions in regulating pulmonary injury through the
generation of reactive oxygen species (ROS) or conducting
phagocytosis and degranulation, recent reports have highlighted
a critical role for NETosis in ALI pathogenesis. NETs consist of a
mix of nuclear chromatin (6), mitochondrial DNA (7–9) and
neutrophil granule proteins (10) that primarily absolve a defensive
role against lung infections. On the other hand, accumulating
evidence indicate that NETosis is also increased in lung sterile
inﬂammatory conditions and that exuberant NET release
promotes microvascular dysfunction, thromboinﬂammation,
and direct cellular injury (11). Moreover, high levels of NETs in
the peripheral blood or bronchoalveolar lavage (BAL) of critically
ill subjects are frequently associated with the worst ARDS
outcomes (12, 13).
In this review, we will discuss general mechanisms of
NETosis and NET-mediated tissue damage (Figure 1) with a
speciﬁc focus on the contribution of NETs to different forms of
infective and sterile ALI (Figure 2).

NET composition
Serine proteases
Under homeostatic conditions, neutrophil azurophilic
granules contain different serine proteases, including neutrophil
elastase (NE), cathepsin G (CatG), proteinase 3 (PR3), and
neutrophil serine protease 4 (NSP4). Due to their antimicrobial
and immunomodulatory function, these pre-stored catalytically
active mediators play a major contribution in the physiological
response to infection (24). However, their uncontrolled
extracellular release may have unintended consequences by
causing damage to the surrounding healthy tissue (25).
Proteomic analysis and studies on the functional activity of
human NETs indicate that NE is the most abundant nonhistone protein and the predominant responsible for the NET
“proteolytic signature” (10, 26). NE is a well-established mediator
of alveolo-capillary permeability where it is thought to trigger
microvascular injury through primarily catalyzing endothelial cell
cadherin proteolysis (27–29). In a mouse model of LPS induced
endotoxemia, treatment with the NE selective inhibitor Sivelestat
attenuated pulmonary endothelial injury reducing endothelial
glycocalyx damage and preserving thrombomodulin and
syndecan-1 expression (30). Similar ﬁndings were observed in
work by Okeke and colleagues, where Sivelestat treatment reduced
NET-mediated injury on human umbilical vein endothelial cells
(HUVECs) (31). Interestingly, Sivelestat was able to reverse the
NET-mediated upregulation of Intercellular Adhesion Molecule-1
(ICAM-1) on HUVECs, suggesting that NETs may propagate the
inﬂammatory response of endothelial cells through NE (31).
Furthermore, reduced NET deposition after Sivelestat treatment
also suggested that NE may be directly involved in the release of
NETs (31). This observation would be consistent with previous
ﬁndings describing the role of NE nuclear translocation in
facilitating histone degradation and chromatin decondensation
(32). However, in mice genetically deﬁcient for NE, the
stimulation with the well-known NETosis inducer, phorbol 12myristate 13-acetate (PMA), does not abrogate the release of

Non-vital and vital NETosis
NETosis was ﬁrst described in 2004 when Brinkman and
coworkers observed that activated neutrophils could kill bacteria
by releasing nuclear chromatin decorated with proteins usually
conﬁned to their granules (14). Following studies characterized
the NADPH oxidase 2 (NOX2) Ros-dependent pathway
involved in the release of NETs and deﬁned NETosis as a new
mechanism of neutrophil programmed cell death distinct from
apoptosis and necrosis (15, 16). NETosis was originally
described as a slow multistep process that leads directly to
senescence, where chromatin decondensation and nuclear
envelope rupture allow for mixing nuclear material with
cytoplasm content. Pore-forming proteins like gasdermin D
then permeabilize the plasma membrane allowing for the
release of NETs into the extracellular space (17). However, this
view of NETosis as a terminal process has been recently
challenged by the demonstration of an alternative, non-lytic
and NADPH-independent mechanism of NET release, which
appears to be particularly rapid in response to bacterial infection
and leaves behind a neutrophil that can still exclude vital dyes
(18). This form of NETosis is initiated by a sudden rise in
intracellular calcium that leads to the expulsion of nuclear
chromatin and granule proteins, resulting in an anucleated
cytoplast still capable of migration and phagocytosis (11, 18,
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FIGURE 1

Mechanisms of NET release and NET-mediated lung injury (A) Neutrophils release NETs in response to endogenous and exogenous stimuli.
Endogenous factors include DAMPs, pro-inﬂammatory cytokines, mtDAMPs, and molecules released by activated platelets; exogenous factors
include PAMPs associated with microbial infections. (B) Inhibition of NET generation and release. The contribution of platelets to NETosis can be
attenuated by using platelet activation inhibitors; neutrophil chromatin decondensation can be targeted by using PAD4 inhibitors; neutrophil
membrane permeabilization can be prevented by using gasderimin D inhibitors. (C) NETs comprise a DNA scaffold decorated with granule
proteases and histone proteins. NET DNA scaffold can be digested by DNase; NET proteolytic activity can be abrogated by speciﬁc protease
inhibitors. (D) NETs release contributes to the pathogenesis of ALI. NETs facilitate the formation of thrombi, promote endothelial cell activation,
and induce microvascular injury. These microvascular alterations result in increased vascular permeability, intra-alveolar accumulation of
protein-rich ﬂuid, and inﬁltration of inﬂammatory cells. Image created by DS using BioRender (https://biorender.com/).

arginine residues into citrulline (37). Citrullination decreases
histone protein stability and facilitates chromatin
decondensation and chromosomal DNA expulsion (38, 39).
PAD4-dependent histones citrullination has been frequently
reported as a critical component of NETosis in response to
numerous physiological stimuli (40), and treatment with PAD4
inhibitors such as Cl-amidine (41) and GSK484 (42) have been
shown positive effects in attenuating ALI. Interestingly, recent
works indicate that there are conditions where NETosis can
occur even in the absence of PAD4 activity, for example, in
response to Candida albicans, Klebsiella pneumoniae or
cholesterol crystals (43–45). These evidence suggest that
during NETosis, chromatin decondensation may be not
exclusively dependent on histone citrullination and that
alternative mechanisms, such as direct histone cleavage by NE
nuclear translocation, may also be involved (32). How different
NET stimuli activate alternative mechanisms of chromatin
decondensation and what is the level of redundancy and
interaction between such pathways remains unclear, indicating
the need for a better characterization of the upstream signaling
involved in NET formation and release.

NETs (33). In addition, the effect of NE inhibition appears to vary
among neutrophils from different healthy donors, suggesting that
NE may not always be necessary for the execution of
NETosis (34).
Other proteases such as PR3 and Cat G are known to
enhance inﬂammatory reactions by modulating the balance
between pro and anti-inﬂammatory proteins (35). However,
despite their documented proteolytic activity in human NETs,
the precise contribution to mediating ALI is currently less clear.
In summary, besides the explicit role of NE in NETmediated lung microvascular damage, the overall contribution
of neutrophil serine proteases to NET-dependent inﬂammation
in ALI is still undeﬁned.

Histones
Histones are generally located within the cell nucleus, where
they play an essential role in organizing and regulating DNA
(36). During NETosis, the enzyme peptidyl arginine deiminase 4
(PAD4) alters histone intermolecular interactions by converting
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FIGURE 2

Association of NETs with different ALI/ARDS etiologies. Image created by DS using BioRender (https://biorender.com/).

example, Saffarzadeh and coworkers show that DNasemediated NET degradation was insufﬁcient to abolish NET
cytotoxicity, suggesting that histone proteins, after DNA
digestion, can still mediate most of the NET-related tissue
damage (51). Similar ﬁndings are also present in work by
Kolaczkowska and colleagues where, in a model of
bloodstream infection with methicillin-resistant
Staphylococcus aureus (MRSA), they demonstrate that
signiﬁcant amount of active histones and NE remained
attached to the vasculature wall after DNase treatment (52).
In summary, extracellular histones play a potent
a nd het erogeneous contri buti on i n NE T- m ed iated
thromboinﬂammation and tissue injury. Reducing the release,
neutralizing, or blocking histone signal transduction may
represent in the future a novel pharmacological approach for
ALI treatment.

Extracellular histones account for ~70% of all NETassociated proteins (10), and their presence highly contributes
to NET-mediated thromboinﬂammation (36, 46). For example,
histone engagement of TLR2 and TLR4 can induce platelet
activation resulting in the release of thrombin (47). In
addition, histones can activate aIIbb3 integrin on the platelet
surface, inducing subsequent ﬁbrinogen-mediated platelet
aggregation (48). Histones also appear to stimulate TLR9dependent responses leading to mitochondrial ROS production
and NLR Family Pyrin Domain Containing 3 (NLRP3)
inﬂammasome activation (49). In a mouse model of ALI
secondary to severe trauma, high circulating histones were
associated with signs of edema, increased alveolar wall
thickening, and occasional hemorrhage (50). However,
inhibition with TLR4 and TLR2-neutralizing antibodies did
not show protective effects on cultured endothelial cells
suggesting that TLR activation may not be the major pathway
for histone toxicity. In this regard, extracellular histones have
been shown to cause endothelial cell damage through direct
interactions with the plasma membrane phospholipids, which
lead to increased transmembrane conductance (50). Although
DNase treatment is generally considered effective in degrading
NET DNA scaffold, questions remain on the fate of NET
proteins, particularly histones, after DNase digestion. For
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NETs can indirectly increase the complement ability to destroy
pathogens such as Pseudomonas aeruginosa and Staphylococcus
aureus (73). Considering the major role played by NETs in
controlling infections, it is not surprising that several microbes
have evolved speciﬁc adaptive strategies to counteract this
defensive mechanism (74). For example, Streptococcus
pneumoniae, the most common cause of community-acquired
pneumonia (CAP), expresses endonucleases that degrade the
NET DNA scaffold allowing for bacterial escape (75). In
alternative, Bordetella pertussis, the causative agent of
whooping cough, expresses adenylate cyclase toxin (ACT)
which inhibits the release of NETs by increasing cAMP levels
and reducing intracellular ROS production (76). In humans, the
critical role of NETs in protecting from lung infections is evident
in subjects affected by Chronic Granulomatous Disease (CDG), a
systemic disorder caused by a genetic deﬁciency in NADPH
oxidase and consequent impairment in NET formation. Initially
described as “a fatal granulomatous disease of childhood’’, CGD
used to be associated with recurrent respiratory infections and
high mortality rate before the introduction of effective
antimicrobial treatments (77). The protective role of NETs,
particularly in the early phase of infection, in controlling
pathogen growth and dissemination is also evident from
experimental observations (78–84). In a mouse model of
polymicrobial sepsis by cecal ligation puncture (CLP),
Czaikoski and coworkers report that DNase treatment
increased systemic bacterial burden and decreased survival
(78). Consistent results were also reported by Meng and
coworkers that, using DNase treatment in a similar mouse
model of sepsis, described a profound and sustainable
reduction of NET-mediated bactericidal activity associated
with worst inﬂammation, more severe organ injury and higher
early mortality (79). Finally, better outcomes in sepsis were
reported by Lee and coworkers in mice deﬁcient for
phospholipase D2 (PLD2) that exhibit an intrinsic upregulation of PAD4 activity associated with augmenting NET
formation and bacterial killing (80).
Although the contribution of NETs in pathogen clearance is
well established, aberrant NET release, particularly into the lung,
has also been associated with the exacerbation of inﬂammation,
immunothrombosis, and tissue injury (85–90). For example,
NETs formed during LPS-induced ALI have been shown to
directly cause organ damage and exacerbate an inﬂammatory
response characterized by leukocyte accumulation, diffuse
alveolar damage and cytokine release which could be
improved by DNase treatment (85). Further details into the
mechanism of NeT-mediated damage during bacterial sepsis
were provided by McDonald and coworkers that recently
described the implication of NET–platelet–thrombin axis in
the promotion of intravascular coagulation and showed that
PAD4 deﬁcient mice or mice that received DNase have reduced
microvascular occlusion and organ dysfunction (86). Blocking

Besides providing a scaffold for the recruitment of platelets,
leukocytes, and coagulation factors (53), cell-free DNA derived
from NETs has been shown to mediate thrombin generation
through the Factor XII- or Factor XI-dependent coagulation
pathways in patients with sepsis (54). Accordingly, the digestion
or precipitation of DNA networks markedly diminishes NET
pro-coagulant effects (55). In addition to nuclear DNA, NETs
can also be enriched with DNA derived from mitochondria
(mtDNA) (7–9). mtDNA are circular molecules of doublestranded DNA that encode for some of the genes that form
the electron transport chain as well as drive mitochondrialspeciﬁc protein synthesis (56). However, given their ancient
bacterial origin (57), NET-associated mtDNA release can act as a
damaged associated molecular pattern (DAMP) by stimulating
the CpG DNA sensor TLR9 (58, 59) as well as triggering NLRP3
inﬂammasome pathway activation on immune cells (60). In
addition, the NET-mediated release of oxidized mtDNA has
been shown to stimulate type I interferon (IFN) signaling
through a signaling pathway dependent on the DNA sensor
stimulator of interferon genes (STING), an intracellular pattern
recognition receptor (9). Moreover, recent ﬁndings indicate that
mtDNA can also directly activate neutrophils to release NETs
through TLR9 engagement (61–63).
In summary, besides acting as a scaffold, NET DNA may
directly stimulate innate immune responses that promote
pulmonary inﬂammation.

NETs and ALI etiologies
Sepsis and pneumonia
Sepsis is a common and deadly inﬂammatory condition
deﬁned as a dysregulated host response to infection associated
with multi-organ dysfunction (64). With the development of
ARDS, lung involvement is frequently observed in critically ill
subjects affected with sepsis (65). Moreover, infectious
pneumonia is one of the leading causes of sepsis and the most
frequent cause of ALI (66–68). Although pathogens themselves
can directly damage the lung, a signiﬁcant contribution to the
injury comes from the exuberant activation of the host immune
cells in response to pathogen-associated molecular patterns
(PAMPs) and DAMPs, collectively deﬁned as “alarmins”
(69–71).
NETs have been ﬁrstly described as a potent defensive
mechanism able to block and inactivate pathogens preventing
their growth and dissemination (14, 72). The cationic NETs
components provide an ideal scaffold for electrostatic
interactions with the negatively charged surface of
microorganisms exposing them to a high local concentration
of cytotoxic molecules. Moreover, even in the absence of direct
killing, experiments in primary human neutrophils showed that
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NETs at the site of infection is essential for controlling pathogen
growth, and defects in NETosis or early NET degradation are
associated with recurrent pneumonia and disseminated
infections. However, NET exuberant release, particularly in a
later phase dominated by post-infectious inﬂammatory events,
appears largely detrimental and concurrently exacerbates tissue
damage and ALI. Possible therapeutic strategies directed to
modulate NET-mediated lung damage during infection should
consider this dynamic relation between the early contribution to
pathogen control and the late post-infectious exacerbation of
systemic inﬂammation.

NET release by pharmacological inhibition of Gasdermin D (91)
or PAD4 (41, 92) similarly reduced signs of sepsis-related multiorgan dysfunction and ALI. Moreover, data on critically ill
subjects affected with infectious pneumonia and sepsis indicate
that higher circulating NETs are associated with the worst
clinical outcomes and directly correlate with organ dysfunction
(12, 69, 93–96). Finally, a meta-analysis of randomized
controlled trials on the use of Sivelestat for the treatment of
ARDS in subjects with sepsis showed improved lung function
even in the absence of a signiﬁcant increased overall
survival (97).
A possible explanation for the complex interplay between
antimicrobial and pro-inﬂammatory NET function has been
recently proposed by Lafrançais and coworkers (95). In this
study, the authors conﬁrmed the presence of higher levels of
NETs in ARDS subjects with infectious etiology that correlated
with the worst clinical outcomes. Moreover, in a mouse model of
bacterial pneumonia, they found that NET release exacerbated
signs of ALI, which could be attenuated in PAD4 deﬁcient mice
or by DNase administration. Interestingly, increased bacterial
growth, particularly observed in mice with a genetic defect in
NETosis, partially counteracted these beneﬁcial effects,
suggesting that the early release of NETs is important in
initially control the infection and that ARDS in sepsis may
represent the maladaptive consequence of this primarily defense
mechanism (95). This view is consistent with previous ﬁndings
showing that early DNase administration in a CLP model of
sepsis increased signs of ALI but that the same treatment
delivered in later phases was beneﬁcial in reducing the level of
systemic inﬂammation and increased survival (98).
In conclusion, the experimental evidence summarized in
Table 1, and the clinical observations from sepsis subjects with
ARDS, indicate that NETs play a dual role in ALI associated with
sepsis and pneumonia. On the one hand, the early release of

COVID-19
COVID-19 is a global pandemic caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) infection,
which in its most severe clinical presentation, is associated with
ALI/ARDS and multiple organ failure (99–101). COVID-19
infection with a high neutrophil-to-lymphocyte ratio is
generally associated with the worst clinical outcomes (102,
103). Neutrophil activation signature is a prominent feature of
circulating leukocyte transcriptomes of severe cases (104, 105).
Additionally, single-cell RNA sequencing (scRNA-seq) analysis
of COVID-19 whole blood samples has revealed distinct
neutrophil clusters associated with NET release and disease
severity (106). In order to characterize COVID-19
immunopathogenesis, several studies have focused on
neutrophil effector functions, and in particular, NETosis (107–
111). SARS-CoV-2 infection has been shown to directly induce
NETosis in healthy neutrophils (111). NETosis has also been
reported as a predictor of COVID-19 severity (110, 112). Postmortem examinations of lungs from COVID-19 patients reveal
diffuse neutrophil inﬁltration with abundant NET deposition

TABLE 1 The effects of NET treatment in experimental models of sepsis.

NET treatment

Sepsis model

Microbial Burden

Tissue Injury

Survival

Reference

DNase (NET digestion)

CLP

Increased

Increased

Reduced

Czaikoski et al. (78)
Meng et al. (79)
McDonald et al. (84)

DNase (NET digestion)

E.Coli IP infection

Increased

Decreased

–

DNase (NET digestion)

MRSA IT infection

No effect

Decreased

Increased

Lafrancais et al. (95)

PAD4-/- (NET inhibition)

MRSA IT infection

Increased

Decreased

No effect

Lafrancais et al. (95)

Alcohol intoxication (NET inhibition)

CLP

Increased

–

Reduced

Jin et al. (82)

DNase (NET digestion) + Antibiotics

CLP

Reduced

Reduced

Increased

Czaikoski et al. (78)

Delayed DNase (NET digestion)

CLP

Reduced

Reduced

Increased

Mai et al. (98)

Disulﬁram (NET inhibition)

CLP

–

Reduced

Increased

Silva et al. (91)

Cl-Amidine (NET inhibition)

CLP

–

–

Increased

Biron et al. (41)

DNase (NET digestion)

LPS

–

Reduced

Increased

Czaikoski et al. (78)

DNase (NET digestion)

LPS

–

Reduced

–

Liu et al. (85)

- , ‘Not Studied’ ; CLP, Cecal Ligation Puncture; LPS, lipopolysaccharide; MRSA, Methicillin-resistant Staphilococcus aureus; E.coli, Escherichia Coli; PAD4, Peptidylarginine deiminase 4;
IP, intra-peritoneal; IT, intra-tracheal.
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reported association of NETs with TRALI, a different study by
Thomas and colleagues found that platelet depletion did not
completely abrogate NETosis and that FcgR engagement by antineutrophil antibodies was sufﬁcient to promote NET release
(124). Moreover, this study showed that DNase administration
effectively prevented NET-mediated ALI only when delivered
through inhalation, probably because of the predominant
accumulation of NETs within alveolar spaces (124). NET
inhibition rather than digestion also appears to be a promising
approach to preventing TRALI as indicated by a recent study
where the administration of Disulﬁram, an FDA-approved
gasdermin D inhibitor for the treatment of alcohol abuse,
prevented signs of lung injury (125).
In summary, NETs appear to have a pathogenic role in
TRALI, and preclinical observations indicate that NET
inhibition or digestion may improve TRALI outcomes.
However, conﬂicting reports as to the speciﬁc contribution of
platelet activation to NET-mediated tissue injury in TRALI
further highlight the need for studies to dissect the molecular
mechanisms of NETosis in vivo.

frequently associated with platelet accumulation and
microvascular thrombosis (113–116). This inﬂammatory
pattern of thrombosis is consistent with ﬁndings from Zuo
and colleagues, who showed a positive correlation between
markedly elevated cell-free DNA and D-dimer levels, a
degradation product of ﬁbrin (110). The pathogenic role of
NET release has also been described in different thrombosismediated inﬂammatory states associated with ARDS (90, 117).
One current view of the underlying causes of ALI-mediated
pulmonary thrombosis is that NET web-like structures
immobilize and activate platelets and leukocytes. Through
mechanisms that have yet to be fully elucidated, this induces a
feed-forward loop that triggers additional intravascular NETosis
and higher local concentrations of histones and proteases that
increase endothelial permeability and promote microvascular
obstruction (117). Given the prominent role of
immunothrombosis in the pathogenesis of COVID-19 ALI/
ARDS, pharmacological NET inhibition or degradation could
represent an intriguing approach to attenuate disease severity
and improve survival. A recent study by Fisher and colleagues
supports this notion by showing remarkable improvement in
clinical outcomes in ﬁve severely ill COVID-19 subjects treated
with off-label aerosolized recombinant human (rh) DNase (118).
Similar ﬁndings were also observed in different single-center
case series and cohort studies where nebulized rhDNase
administration showed favorable clinical outcomes in the
absence of drug-associated toxicities (119, 120). Although the
results from these small observational studies are encouraging,
larger and randomized clinical trials will be required to assess the
long terms effects of DNase treatment on COVID-19 ARDS.

Lung ischemia-reperfusion injury (LIRI)
LIRI is a primarily sterile inﬂammatory disease occurring in
lungs that sustain ischemic damage followed by reperfusion.
LIRI is typically associated with pulmonary embolisms and
various cardiothoracic surgical procedures, including lung
transplantation (LTx) (128). The physiopathological
mechanisms of LIRI are incredibly complex (129), and the
speciﬁc contribution of neutrophils is still debated (130, 131).
The prevailing view is that LIRI is a bimodal process, with an
early phase primarily dependent on pulmonary macrophages
and activated platelets followed by later neutrophil-mediated
damage (132–134).
A recent study by Sayah and colleagues demonstrated a
pathogenic role for NETs in primary graft dysfunction (PGD), a
common form of LTx-related LIRI occurring within 72 hours.
after surgery. Using a mouse model of syngeneic orthotopic left
lung transplant (OLT), this group detected the presence of intragraft NETs in association with platelet activation. Pretreatment
with aspirin or intrabronchial administration of DNase were
both able to attenuate signs of PGD in the OLT model (135). A
later study by our group extended these ﬁndings by visualizing
intragraft NETosis by intravital 2-photon microscopy in an
allogeneic mouse model of OLT. Interestingly, the systemic
administration of DNase improved lung function but at the
cost of increasing alloimmune responses and graft rejection due
to the release of inﬂammatory NET fragments. However, directly
targeting NET generation by the genetic deletion or
pharmacological inhibition of PAD4 prevented alloimmune
responses and allograft rejection (136). The unintended
consequences associated with NET digestion have been

Transfusion-related acute lung
injury (TRALI)
TRALI is a form of ALI that occurs within six hours of
transfusion that cannot be explained by another ALI risk factor
(121). Neutrophil activation and sequestration within the
pulmonary capillaries in response to blood components is
considered a central feature in the pathogenesis of TRALI
(122). Recent insights into the mechanisms of neutrophilmediated tissue damage indicate that NETs form in the lung
and contribute to the pathogenesis of this disease (123–125).
Using an established mouse model of TRALI (126), Caudrillier
and coworkers show that platelet sequestration increases with
NET proximity and that aspirin treatment decreases NET
formation and NET-associated platelets (123). Moreover,
human platelets activated with the PAR-1 agonist, thrombin
receptor-activating peptide (TRAP), induced robust NET release
via Thromboxane A2 (123). Further investigation into how
platelets drive NETosis revealed dependence on the canonical
Raf/MEK/ERK signaling pathway that is also critical to PMAinduced NADPH-dependent NETosis (127). Despite the

Frontiers in Immunology

07

frontiersin.org

Scozzi et al.

10.3389/ﬁmmu.2022.953195

contrast to these ﬁndings, Rossaint and coworkers found that
targeting NETs with DNase effectively protected mice from ALI
in a single hit model of VILI (150). Moreover, the group further
demonstrated that VILI-induced NETosis is a plateletdependent process requiring simultaneous stimulation of
integrins and G-protein–coupled receptors on neutrophils
(150). Using the same single hit model of VILI, Li and
coworkers conﬁrmed the beneﬁcial effect of DNase treatment
in preventing ALI and showed that TLR4 signaling is implicated
in the release of NETs in VILI (151).
In summary, the current evidence shows that NETs are
released during VILI and that targeting NETs may be beneﬁcial
in preventing injury in this setting. The differing effects observed
with DNase treatment may be related to the use of alternative
experimental models suggesting further pre-clinical evaluation is
likely necessary to better characterize the effects of NETosis
on VILI.

increasingly described in different animal models, raising the
question of whether it is more effective to prevent NETosis in
lieu of DNase treatment (137). For example, NETs have been
described to merge in high-density structures named aggNETs,
which are thought to prevent bystander tissue injury as well as
contribute to wound healing and inﬂammation resolution
through driving the proteolytic degradation of cytokines and
histones (138–140). Most recently, our group has provided
further insight into the mechanisms of NET-mediated graft
injury by showing that necroptosis, occurring in response to
warm-ischemia, drives early neutrophil accumulation into the
sub-pleural capillary network resulting in NET-mediated
microvascular damage (59). Necroptosis is a Receptor
Interacting Serine/Threonine Kinase 3 activation-mediated
form of cell death that leads to the extracellular release of
various alarmins, including mitochondrial-derived DAMPs
(mtDAMPs) (141). Additionally, our group and others have
shown that LIRI leads to the release of mtDAMPs, which guide
neutrophil intragraft trafﬁcking, stimulate ROS production and
trigger NETosis (61, 142).
Altogether, the observations from the LIRI models and
human LTx recipients with PGD support the notion that
DAMPs released from the ischemic tissues induce innate
immune responses resulting in NETosis and tissue injury.
Interfering with the mechanisms that activate NETosis rather
than enhancing the degradation of NETs appears a more
desirable option for attenuating LTx-related ALI without
increasing the risk of allograft rejection.

Trauma
Trauma is deﬁned as an injury caused by an external
physical force, as it may result in the consequence of blunt
force impact, penetrating injuries, or extensive thermal and
chemical burns. Although advancements in surgery and
resuscitation have substantially increased the chance of
surviving a major trauma, some patients still develop
systemic inﬂammatory response syndrome (SIRS) and
infections (152). ARDS is a well-known complication of
major trauma, and it represents one of its leading causes of
death (153). Trauma is commonly associated with the loss of
natural barrier function, which places large demands on
neutrophils to scavenge tissue debris and control the
diffusion of pathogens. However, due to the large
microvascular bed and the long transit time, the lung
represents a preferred site for the accumulation of activated
neutrophils after trauma (154). NET release has been
demonstrated in several experimental models of trauma (63,
155–157), and elevated levels of circulating NET markers have
been associated with the worst clinical outcomes in subjects
developing trauma-related ARDS (50). Interestingly, ARDS
resulting from trauma seems to be overall associated with
better clinical outcomes when compared to other forms of
ARDS, suggesting the presence of peculiar immunological
features (158–161). In this regard, trauma is a known driver
of emergency hematopoiesis leading to a high number of
circulating immature neutrophils (162) with impaired
effector functions (163, 164). In addition, trauma induces the
expansion of speciﬁc neutrophil subsets that are either
unresponsive or display immunosuppressive activity,
increasing the risk of secondary infections (165–167). Recent
work by Hazeldine and colleagues has suggested that reduced
neutrophil activity in the trauma setting is related to their

Ventilator-induced lung injury (VILI)
VILI is a form of ALI triggered by mechanical ventilation
(143). Neutrophil recruitment in response to VILI is driven by Lselectin expression and is promoted by stretch-induced
inﬂammatory events (144) that lead to the release of
neutrophil chemokines such as CXCL1 (KC) and CXCL2/3
(MIP-2) (145). Short periods of mechanical ventilation have
been shown to be associated with the release of proinﬂammatory cytokines, including TNF-a, IL-1b and IL-8
(146, 147), which are well-known activators of NETosis (148).
Accordingly, recent studies have focused on the possible
contribution of NETs to VILI pathogenesis. Using a “doublehit” model of intra-tracheal LPS challenge followed by high tidal
mechanical ventilation, Yildiz and colleagues showed that VILI
is associated with signiﬁcant NET release. DNase, also
administrated intratracheally, reduced BAL markers of NETs
and improved lung compliance but did not affect other measures
of lung injury including oxygenation, inﬂammatory cell
inﬁltration and lung permeability (149). The singular
improvement in lung compliance led the authors to
hypothesize that DNase treatment decreased airway secretion
viscosity rather than imparting VILI protection (149). In
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for all forms of NETosis, given the apparent redundancy in the
pathways that generate NETs. Platelet activation and
coagulation factors appear to be highly interconnected with
NET release leading to a state of thromboinﬂammation (176).
Although this mechanism appears to be extremely relevant in
the ARDS associated with COVID-19, its contribution still needs
to be precisely characterized for other ALI etiologies. In addition,
the molecular details that control the crosstalk between innate
immunity and coagulation remain poorly understood. DAMPs,
particularly those derived from mitochondria, appear to be
strongly involved in the activation of NETosis (61, 62).
Interfering with their signals may represent a promising
strategy to reduce exuberant NET release and prevent
neutrophil desensitization to microbial PAMPs. However, to
safely leverage these observations, pathways that control the
delicate balance between neutrophil activation and
desensitization will need further investigation.
In conclusion, future studies that better deﬁne the
mechanisms involved in the formation, release, and degradation
of NETs could form the basis of therapeutic strategies that target
ALI without disabling pathogen surveillance.

ability to form NETs (168). This group demonstrated that a few
minutes after the injury, neutrophils exhibit an activated
phenotype characterized by enhanced glucose metabolism
and NETosis. However, hours later, neutrophils became
unresponsive, and their ability to form NETs dramatically
decreased. To explain this apparent change in neutrophil
function, the authors hypothesize that mtDAMPs, such as Nformylated peptides, desensitize neutrophils to further
stimulation, effectively reducing their ability to release NETs
(168). Recent ﬁndings from Itagaki and colleagues support the
existence of this regulatory pathway. They showed that
blocking the N-formylated peptide receptor-1 (FPR1)
preserves neutrophil function after trauma (169). Other
evidence, however, point to the pro-inﬂammatory role of
mtDAMPs in activating neutrophils (58, 170, 171), increasing
NETosis (61, 62), and predisposing to the development of SIRS
(172). Further complicating this picture, studies of trauma
subjects show reduced endogenous DNase activity and
increased circulating cell-free DNA levels associated with
post-injury complications (164, 173, 174). Despite the
general state of immune unresponsiveness and the increased
risk of infection, these studies suggest that restoring DNase
activity is likely beneﬁcial after trauma.
In summary, ALI associated with trauma appears to display
peculiar immunological features, possibly related to the sudden
and massive release of DAMPs and the alteration of regulatory
mechanisms that promote DAMP clearance. How different
DAMPs control neutrophil metabolism, differentiation and
NETosis as well as shape host responses to trauma remains to
be determined.
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can predict worst clinical outcomes in ARDS subjects (5). Most
of the current literature has focused on the use of DNase in
preventing NET-mediated ALI (175). However, although DNase
has shown promising results in reducing signs of lung injury and
inﬂammation associated with NET release, several questions
about its global use to treat ARDS conditions remain. For
example, does DNase-mediated NET degradation increase the
risk of infection? In addition, do the rapid release of histones and
proteases following DNAse treatment have unintended effects
on outcomes? Preventing formation rather than digesting NETs
may offer a more suitable alternative strategy to treat some forms
of ALI. In this regard, selective inhibitors have been developed to
prevent the generation and release of NETs at different stages of
NETosis (17, 37). Nevertheless, it remains to be determined if
NET formation inhibitors will be effective for most forms of ALI
and, like DNase, could potentially dysregulate host defense. It
also remains to be determined if NET inhibitors will be effective
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Melo PH, et al. Neutrophil extracellular traps induce organ damage during
experimental and clinical sepsis. PloS One (2016) 11:e0148142. doi: 10.1371/
journal.pone.0148142

55. Yang J, Wu Z, Long Q, Huang J, Hong T, Liu W, et al. Insights into
immunothrombosis: The interplay among neutrophil extracellular trap, Von
willebrand factor, and ADAMTS13. Front Immunol (2020) 11:610696.
doi: 10.3389/ﬁmmu.2020.610696
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Gonç a lves AV, et al. Gasdermin d inhibition prevents multiple organ
dysfunction during sepsis by blocking NET formation. Blood (2021) 138:2702–
13. doi: 10.1182/blood.2021011525

113. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J,
Crawford JM, et al. Targeting potential drivers of COVID-19: Neutrophil
extracellular trapsneutrophil extracellular traps in COVID-19. J Exp Med (2020)
217:e20200652. doi: 10.1084/jem.20200652

92. Li Y, Liu Z, Liu B, Zhao T, Chong W, Wang Y, et al. Citrullinated histone H3
– a novel target for treatment of sepsis. Surgery (2014) 156:229–34. doi: 10.1016/
j.surg.2014.04.009

114. Parra-Medina R, Herrera S, Mejia J. Systematic review of microthrombi in
COVID-19 autopsies. Actq Haematol (2021), 144(5):476-83. doi: 10.1159/000515104

93. Margraf S, Lögters T, Reipen J, Altrichter J, Scholz M, Windolf J.
Neutrophil-derived circulating free DNA (Cf-DNA/NETs): A potential
prognostic marker for posttraumatic development of inﬂammatory second hit
and sepsis. Shock (2008) 30:352–8. doi: 10.1097/SHK.0b013e31816a6bb1

115. Fang X-Z, Wang Y-X, Xu J-Q, He Y-J, Peng Z-K, Shang Y.
Immunothrombosis in acute respiratory dysfunction of COVID-19. Front
Immunol (2021) 12:651545. doi: 10.3389/ﬁmmu.2021.651545
116. Middleton EA, He X-Y, Denorme F, Campbell RA, Ng D, Salvatore SP, et al.
Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute
respiratory distress syndrome. Blood (2020) 136:1169–79. doi: 10.1182/blood.2020007008

94. Maruchi Y, Tsuda M, Mori H, Takenaka N, Gocho T, Huq MA, et al. Plasma
myeloperoxidase-conjugated DNA level predicts outcomes and organ dysfunction
in patients with septic shock. Crit Care (2018) 22:176. doi: 10.1186/s13054-0182109-7

117. Frantzeskaki F, Armaganidis A, Orfanos SE. Immunothrombosis in acute
respiratory distress syndrome: Cross talks between inﬂammation and coagulation.
RES (2017) 93:212–25. doi: 10.1159/000453002
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